Topline results from the Phase 3 trial, APPEAR-C3G, showed Fabhalta (iptacopan) met its primary endpoint in reducing protein in the urine in patients with C3G.
Celldex’s lead asset shows promise in 2 skin conditions
Celldex’s CSU, PN trials represent not only strong datasets but suggest barzolvolimab’s ‘pipeline-in-a-product potential’ in other mast cell-driven diseases.
Syndax’s acute leukemia drug succeeds in pivotal study
Supported by the hashtag #RaisingHealth, the campaign debuted with a 30-second ad titled “The Solvers,” which also ran on Northwell’s LinkedIn page, which has more than 178,000 followers.
Biogen’s Aduhelm marketing plan targeted communities of color — but clinical trials included very few non-white participants